Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| INSM - Insmed | 18.52% | Reduce −12.4% | 865,113 | $100.64 | $87M | −122,040 | +$12M |
| ACAD - Acadia Pharmaceuticals | 11.76% | Reduce −3.8% | 2,563,209 | $21.57 | $55M | −100,716 | +$11M |
| BMRN - Biomarin Pharmaceutical | 9.83% | Reduce −15.2% | 840,470 | $54.97 | $46M | −150,737 | −$24M |
| FOLD - Amicus | 6.84% | Reduce −23.6% | 5,610,513 | $5.73 | $32M | −1,734,489 | −$28M |
| UTHR - United Therapeutics | 5.84% | Reduce −9.3% | 95,482 | $287.35 | $27M | −9,746 | −$5M |
| BIIB - Biogen | 5.50% | Add +0.4% | 205,759 | $125.59 | $26M | +836 | −$2M |
| ALNY - Alnylam Pharmaceuticals | 5.24% | Reduce −9.5% | 75,535 | $326.09 | $25M | −7,953 | +$2M |
| PTC - Ptc Therapeutics | 4.22% | Add +0.6% | 406,469 | $48.84 | $20M | +2,273 | −$746K |
| ANAB - Anaptysbio | 3.84% | Reduce −20.4% | 812,821 | $22.20 | $18M | −207,892 | −$930K |
| NVCR - Novocure | 3.64% | Reduce −4.0% | 962,396 | $17.80 | $17M | −39,665 | −$726K |
| Staar Surgical | 2.83% | Add +50.8% | 791,879 | $16.78 | $13M | +266,862 | +$4M |
| AGIO - Agios Pharmaceuticals | 1.90% | Reduce −2.8% | 268,783 | $33.26 | $9M | −7,795 | +$836K |
| PRTA - Prothena · CL A | 1.65% | Reduce −23.2% | 1,274,753 | $6.07 | $8M | −384,981 | −$13M |
| IRON - Disc Medicine | 1.64% | New | 145,691 | $52.96 | $8M | +145,691 | +$8M |
| ALGN - Align Technology | 1.52% | Hold | 37,772 | $189.33 | $7M | — | — |
| Gossamer Bio | 1.50% | Reduce −8.6% | 5,739,013 | $1.23 | $7M | −537,880 | +$154K |
| EHTH - Ehealth | 1.46% | Reduce −6.3% | 1,577,850 | $4.35 | $7M | −106,486 | −$4M |
| ALKS - Alkermes | 1.35% | Reduce −0.2% | 221,021 | $28.61 | $6M | −492 | −$991K |
| IOVA - Iovance Biotherapeutics | 1.25% | Add +6.8% | 3,429,329 | $1.72 | $6M | +218,015 | −$5M |
| SNDX - Syndax Pharmaceuticals | 0.89% | Hold | 444,367 | $9.37 | $4M | — | — |
| RNAGBP - Avidity Biosciences | 0.72% | New | 118,886 | $28.40 | $3M | +118,886 | +$3M |
| DNLI - Denali Therapeutics | 0.71% | New | 239,809 | $13.99 | $3M | +239,809 | +$3M |
| MIRM - Mirum Pharmaceuticals | 0.70% | Hold | 64,700 | $50.89 | $3M | — | — |
| EW - Edwards Lifesciences | 0.66% | Hold | 39,473 | $78.21 | $3M | — | — |
| TSHA - Taysha Gene Therapies | 0.61% | Reduce −12.2% | 1,246,033 | $2.31 | $3M | −173,435 | +$905K |
| BNTX - Biontech Se- | 0.57% | Hold | 25,206 | $106.47 | $3M | — | — |
| DYN - Dyne Therapeutics | 0.54% | Reduce −20.5% | 264,976 | $9.52 | $3M | −68,415 | −$965K |
| CRSP - Crispr Therapeutics AG | 0.46% | New | 44,625 | $48.64 | $2M | +44,625 | +$2M |
| ACRS - Aclaris Therapeutics | 0.42% | Add +79.1% | 1,390,028 | $1.42 | $2M | +614,000 | +$787K |
| RARE — | 0.38% | New | 48,750 | $36.36 | $2M | +48,750 | +$2M |
| BCYC — | 0.37% | Hold | 248,934 | $6.95 | $2M | — | — |
| NBIX - Neurocrine Biosciences | 0.36% | Hold | 13,334 | $125.69 | $2M | — | — |
| TVTX - Travere Therapeutics | 0.35% | Hold | 110,719 | $14.80 | $2M | — | — |
| NUVB - Nuvation Bio | 0.32% | Hold | 772,652 | $1.95 | $2M | — | — |
| STOK - Stoke Therapeutics | 0.30% | Hold | 125,861 | $11.35 | $1M | — | — |
| PYXS - Pyxis Oncology | 0.24% | Hold | 1,037,421 | $1.10 | $1M | — | — |
| HUM - Humana | 0.21% | Hold | 3,985 | $244.48 | $974K | — | — |
| ALDX - Aldeyra Therapeutics | 0.18% | Hold | 225,465 | $3.83 | $864K | — | — |
| KPTI - Karyopharm Therapeutics | 0.17% | New | 187,911 | $4.31 | $810K | +187,911 | +$810K |
| Vyne Therapeutics Pipe | 0.16% | Hold | 445,434 | $1.65 | $735K | — | — |
| ABEO - Abeona Therapeutics | 0.13% | Hold | 108,865 | $5.68 | $618K | — | — |
| ALMS - Alumis | 0.09% | New | 143,437 | $3.00 | $430K | +143,437 | +$430K |
| URGN - Urogen Pharma | 0.07% | Hold | 24,500 | $13.70 | $336K | — | — |
| Akari Therapeutics - | 0.04% | Hold | 146,024 | $1.17 | $171K | — | — |
| Generation Bio | 0.01% | Hold | 150,475 | $0.3201 | $48K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics | 2.56% | Exit | 0 | $63.82 | $13M | −210,258 | −$13M |
| Acelyrin | 0.84% | Exit | 0 | $2.47 | $4M | −1,792,895 | −$4M |
| Verve Therapeutics | 0.50% | Exit | 0 | $4.57 | $3M | −575,817 | −$3M |
| Karyopharm Therapeutics | 0.23% | Exit | 0 | $3.74 | $1M | −324,032 | −$1M |
| Instil Bio | 0.04% | Exit | 0 | $17.38 | $194K | −11,165 | −$194K |
| RLMD - Relmada Therapeutics | 0.03% | Exit | 0 | $0.2706 | $134K | −495,146 | −$134K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2